FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition for local application for preventing or treating herpes virus infection in humans. Above composition contains 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or its pharmaceutically acceptable salt in amount of 0.1–10 wt/wt% in pharmaceutically acceptable carrier.
EFFECT: invention provides evident therapeutic effect of herpetic infection.
5 cl, 1 ex
Authors
Dates
2017-01-26—Published
2012-02-17—Filed